This article is more than 5 years old. Information may no longer be current.

Allergan pharmaceutical sales up 15% over third quarter of 2003

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan’s net sales were $510 million during the third quarter of 2004, with an increase of 15% in pharmaceutical sales over the third quarter of 2003, the company announced in a press release.

During the third quarter, eye care pharmaceutical sales rose to $285.4 million from $252.8 million in the same quarter 1 year ago, the company announced. The strongest sales were reported for glaucoma medications Alphagan P (brimonidine with Purite preservative), Alphagan (brimonidine) and Lumigan (bimatoprost). Lumigan showed the largest jump in sales, from $46.9 million in the third quarter of 2003 to $60.3 million in the third quarter of 2004. Other leading eye care medications included Restasis (cyclosporine) for dry eye.

Botox (botulinum toxin) posted sales of $174.6 million during the third quarter of 2004, an increase of $34.7 million from the same quarter in 2003.

Other highlights from the quarter included the receipt of an “approvable” letter from the Food and Drug Administration for a fixed combination of bimatoprost and timolol, according to the press release.